Next-Generation Sequencing

New data have linked next-generation sequencing with improved overall survival in ovarian cancer, according to a presenter at the virtual ASCO Annual Meeting.

In February, ASCO named molecular profiling driving progress in gastrointestinal cancers as its “Advance of the Year.” According to the American Cancer Society, taken collectively, gastrointestinal cancers have the highest incidence in the U.S. and, after lung cancer, are the second leading cause of cancer-related death. Identifying smaller subsets of patients based on tumor-specific and tumor-agnostic alterations provides insight as to who will benefit from personalized therapies. These subsets ultimately end up being substantial in size and, thus, universal testing should indeed be standard of care for all patients with metastatic gastrointestinal cancer.

In 2010, results of the phase 2 BATTLE study demonstrated that choice of cancer therapy could be individualized based upon a patient’s tumor characteristics.

Only one in four Black patients with advanced or metastatic non-small cell lung cancer underwent next-generation sequencing before first-line therapy compared with one in three white patients, according to results of a retrospective study.

Next-generation sequencing may help identify gene variants linked to inborn errors of metabolism among a subgroup of patients with psychosis, according to study results published in Journal of Psychiatric Research.

As difficulties exist in the diagnosis of infection in orthopedic surgery, researchers have turned their attention to serum markers, next-generation sequencing and phage therapy as possible diagnosis solutions, according to a presenter.

The FDA approved FoundationOne Liquid CDx, a comprehensive pan-tumor liquid biopsy test.

The FDA today approved Guardant360 CDx, a liquid biopsy companion diagnostic that uses next-generation sequencing, to identify EGFR mutations in patients with metastatic non-small cell lung cancer.